Summarized by Masters of Longevity from PR Newswire.
Report on a preclinical therapeutic approach that targets capillary no-reflow after heart attack using a capillary-selective vasodilator to restore microvascular perfusion.
Key Takeaways
- Researchers identified a smooth-muscle-myosin inhibitor that relaxes capillary hypercontraction and restores blood flow within seconds.
- PeriFlow’s lead candidate CLN-2501 reduced tissue injury and improved survival in preclinical and large-animal myocardial infarction models.
- The company plans to advance CLN-2501 toward clinical development in the United States, expanding a portfolio of tissue-selective myosin inhibitors.
